Abstract
Objective
To examine the applicability of 10 common clinical practice guidelines (CPGs) to elderly patients with multiple comorbidities.
Design
Content analysis of published Canadian CPGs for the following chronic diseases: diabetes, dyslipidemia, dementia, congestive heart failure, depression, osteoporosis, hypertension, gastroesophageal reflux disease, chronic obstructive pulmonary disease, and osteoarthritis.
Main outcome measures
Presence or absence of 4 key indicators of applicability of CPGs to elderly patients with multiple comorbidities. These indicators include any mention of older adults or people with comorbidities, time needed to treat to benefit in the context of life expectancy, and barriers to implementation of the CPG.
Results
Out of the 10 CPGs reviewed, 7 mentioned treatment of the elderly, 8 mentioned people with comorbidities, 4 indicated the time needed to treat to benefit in the context of life expectancy, 5 discussed barriers to implementation, and 7 discussed the quality of evidence.
Conclusion
This study shows that although most CPGs discuss the elderly population, only a handful of them adequately address issues related to elderly patients with comorbidities. In order to make CPGs more patient centred rather than disease driven, guideline developers should include information on elderly patients with comorbidities.
Résumé
Objectif
Déterminer l’applicabilité aux patients âgés qui souffrent de multiples affections de 10 directives de pratique clinique (DPC) courantes.
Type d’étude
Analyse de contenu des DPC canadiennes pour les maladies chroniques suivantes : diabète, dyslipidémie, démences, insuffisance cardiaque, dépression, ostéoporose, hypertension, reflux gastro-œsophagien, maladie pulmonaire obstructive chronique et arthrose.
Principaux paramètres à l’étude
Présence ou absence de 4 indicateurs clés de l’applicabilité des DPC aux patients avec comorbidité. Ces indicateurs incluent toute mention d’adultes âgés ou de sujets avec comorbidité, durée du traitements nécessaire pour obtenir un avantage compte tenu de l’espérance de vie et obstacles à la mise en œuvre des DPC.
Résultats
Sur les 10 DPC à l’étude, 7 parlaient du traitement des personnes âgées, 8 mentionnaient les patients avec comorbidité, 4 indiquaient le temps de traitement nécessaire pour obtenir un avantage compte tenu de l’espérance de vie, 5 discutaient des obstacles à l’application des DPC et 7 de la qualité des preuves.
Conclusion
Cette étude montre que même si la plupart des DPC font mention de la population âgée, très peu discutent adéquatement des problèmes des patients âgés avec comorbidité. Afin que les DPC soient davantage centrées sur les patients plutôt que sur les maladies, les concepteurs des directives devraient inclure des informations sur les patients avec comorbidité.
Clinical practice guidelines (CPGs) are defined as “systematically developed statements to assist practitioners’ and patients’ decisions about appropriate health care for specific clinical circumstances.”1 Clinical practice guidelines are developed to assist clinicians in providing the best care using the most recent evidence. There have been debates among physicians about the usefulness of CPGs in improving the quality of care of patients.2–7 Proponents of CPGs encourage the use of CPGs in order to reduce variation and arbitrariness in practice, as well as to improve the quality of care.4,5 Opponents of CPGs cite a lack of improvement in the quality of care despite wide dissemination of guidelines; potential conflict of interest, especially in CPGs sponsored by industries; a lack of comprehensiveness of CPGs to all domains of medicine; and contradictory recommendations among multiple CPGs within the same disease category.2,3,6,8 Recent studies have focused on various aspects of CPGs, such as incorporation of patients’ values and treatment preferences in therapeutic decision making9 and adherence to established methodologic standards.10
Clinical practice guidelines have been criticized as being “disease driven rather than patient driven.”11,12 Disease-specific CPGs are particularly challenging to apply to elderly patients with multiple comorbidities. Studies done in the United States13 and Australia14 have shown that about half of the reviewed CPGs addressed this population.
The Canadian population is aging. Between 1981 and 2005, the number of seniors (≥ 65 years of age) in Canada increased from 2.4 to 4.2 million. It is projected that by 2036 seniors will account for more than a quarter of the Canadian population.15 Up to 81% of seniors living in the community have at least 1 chronic condition, and 33% have 3 or more chronic conditions.16 Primary care physicians, the primary users of CPGs, are increasingly providing care to elderly patients with multiple comorbidities. These providers require improved CPGs with specific recommendations targeting elderly patients with multiple comorbidities. To the best of our knowledge, no Canadian studies have examined the applicability of CPGs to elderly patients with multiple comorbidities. Therefore, the purpose of this study was to examine the applicability of common CPGs to elderly patients with multiple comorbidities.
METHODS
We conducted a content analysis of the most recently published Canadian CPGs. Two independent reviewers (D.R.M. and H.G.) conducted the analysis separately and then compared the results. Consensus was reached at the end of the review to finalize the results. Clinical practice guidelines were selected on 2 rationales: 1) most prevalent chronic conditions17 in the elderly population, and 2) most common medications prescribed to the elderly population in Ontario during a 10-year period (1997 to 2006).18 We mapped the top 10 prescription claims with the top 10 common chronic diseases managed by primary care physicians (Table 117,18). Most CPGs were identified from the Canadian Medical Association Infobase website19 and a few were obtained by using the Google search engine. We selected 10 CPGs that were most relevant to and most likely to be used by family physicians.
Table 1.
MEDICATIONS | CORRESPONDING CHRONIC DISEASES |
---|---|
Osteoporosis medications | Osteoporosis |
Lipid-lowering agents | Dyslipidemia |
Thyroid replacement therapy | Hypothyroidism |
Psychotropic drugs | Depression or dementia |
Cardiovascular medications | Hypertension, congestive heart failure |
Diabetes medications | Diabetes |
Gastrointestinal medications | Gastroesophageal reflux disease |
Narcotics, analgesics, or NSAIDs | Osteoarthritis |
Asthma or COPD therapies | COPD |
Definitions of main outcome measures
The main outcome measures (ie, mention of older adults or people with comorbidities, time needed to treat in the context of life expectancy, and barriers to implementation) were selected from previous studies that examined applicability of CPGs to elderly patients.13,14
We defined elderly as people older than 65 years of age. When no specific age was indicated, we looked for words that signified older age in the CPGs (eg, senior, older adults, frail elderly).
The applicability of CPGs to people with comorbidities was determined by scanning CPG documents for any mention of people with 1 or more chronic conditions in addition to the primary disease that would affect treatment choices.
The outcome of time needed to treat in the context of life expectancy has also been used in previous literature.13,14 It refers to specific recommendations on how to modify treatment for the elderly in the context of life expectancy. The recommendations must balance the risks and benefits to the patient; specifically, the guidelines should address the treatment within the context of life expectancy, prognosis, quality of life, or end-of-life care.
Finally, the outcome measure of barriers to implementation includes explicit statements that help clinicians to understand the limitations that might pose difficulty in executing the recommendations.
Data collection and analysis
Relevant data were extracted using a data collection sheet. The data collection sheet was constructed from existing validated instruments, including the Appraisal of Guidelines for Research and Evaluation instrument20,21 and a checklist for reporting CPGs developed by the Conference on Guideline Standardization,22 and other published studies that focused on applicability of CPGs to elderly patients with multiple comorbidities.13,14 The final data collection sheet included 4 key indicators: any mention of older adults, mention of people with comorbidities, time needed to treat to benefit in the context of life expectancy, and barriers to implementation of the CPG. Data were collected, summarized, and tabulated in an Excel spreadsheet.
RESULTS
Table 223–38 is an overview of CPGs we reviewed. The CPGs were published between 2005 and 2009. With the exception of the osteoarthritis CPG (developed by British Columbia’s Ministry of Health Services),23 the CPGs were developed by various Canadian national organizations or societies. At the time of data collection, there were no CPGs for managing thyroid diseases.
Table 2.
DISEASE | CLINICAL PRACTICE GUIDELINES |
---|---|
Osteoarthritis | Guidelines and Protocols Advisory Committee,23 2008 |
Osteoporosis | Brown et al,24 2006 |
Dyslipidemia | Genest et al,25 2009 |
Diabetes | Canadian Diabetes Association,26 2008 |
Hypertension | Canadian Hypertension Education Program,27 2009 |
Congestive heart failure | Arnold et al,28 2006 |
Gastroesophageal reflux disease | Armstrong et al,29 2005 |
Chronic obstructive pulmonary disease | O’Donnell et al,30 2008 |
Depression | Buchanan et al,31 2006 |
Dementia | Hogan et al,32,33 2008; Patterson et al,34 2008; Feldman et al,35 2008; Herrmann and Gauthier,36 2008; Chertkow et al,37 2008; Chertkow,38 2008 |
Table 323–28,30–38 shows tabulation of each applicability indicator included in the CPGs. Out of 10 CPGs reviewed, 7 mentioned treatment of the elderly, 8 mentioned people with comorbidities, 4 indicated the time needed to treat to benefit in the context of life expectancy, 5 discussed barriers to implementation, and 7 discussed the quality of evidence.
Table 3.
INDICATORS | NO. OF CPGs APPLICABLE | APPLICABLE CPGs, BY DISEASE |
---|---|---|
Treatment of elderly | 7 | Osteoporosis,24 dyslipidemia,25 diabetes,26 HTN,27 CHF,28 depression,31 dementia32–38 |
People with comorbidities | 8 | Osteoarthritis,23 diabetes,26 HTN,27 CHF,28 depression,31 dementia,32–38 COPD,30 dyslipidemia25 |
Time needed to treat to benefit in the context of life expectancy | 4 | CHF,28 COPD,30 depression,31 diabetes26 |
Barriers to implementation | 5 | Diabetes,26 HTN,27 CHF,28 depression,31 dementia32–38 |
Quality of evidence | 7 | Dyslipidemia,25 HTN,27 CHF,28 depression,31 diabetes,26 dementia,32–38 COPD30 |
CHF—congestive heart failure, COPD—chronic obstructive pulmonary disease, CPGs—clinical practice guidelines, HTN—hypertension.
Recommendations specific to the elderly
Table 424–28,31–38 shows examples of statements and recommendations about issues related to the elderly in CPGs. With the exception of the dementia32–38 and congestive heart failure28 (CHF) CPGs, the rest of the CPGs specified the applicable age in their recommendations. Two CPGs (diabetes26 and CHF28) used words such as elderly or frail elderly. The diabetes26 and depression31 CPGs provided evidence that treatment response was similar in older people and in the younger population. Three CPGs (diabetes,26 hypertension,27 and depression31) provided a list of suitable and unsuitable pharmacotherapy and nonpharmacologic therapies to be used in elderly patients.
Table 4.
CLINICAL PRACTICE GUIDELINE, BY DISEASE | SPECIFICATION OF AGE | STATEMENTS AND RECOMMENDATIONS ABOUT ISSUES RELATED TO THE ELDERLY (LEVELS OF EVIDENCE OR GRADES OF RECOMMENDATION*) |
---|---|---|
Congestive heart failure28 | No (guideline uses the words elderly or frail elderly) |
|
Dementia32–38 | No | NA (involves elderly by default of natural history of disease) |
Depression31 | Yes |
|
Diabetes26 | Yes (> 60 y) |
|
Dyslipidemia25 | Yes (men ≥ 50 y, women ≥ 60 y) |
|
Hypertension27 | Yes (≥ 50 y, ≥ 60 y, ≥ 80 y) |
|
Osteoporosis24 | Yes (> 50 y) |
|
ASA—acetylsalicylic acid, CHEP—Canadian Hypertension Education Program, NA—not applicable, SSRI—selective serotonin reuptake inhibitor.
Levels of evidence and grades of recommendation are based on the categories used by individual articles.
Recommendations for people with comorbidities
Table 523,25–28,30–38 provides a summary of CPGs that mentioned or addressed people with comorbidities. Two CPGs (CHF28 and depression31) recommend multidisciplinary and interdisciplinary care of patients with multiple comorbidities. In addition, the diabetes26 CPG recommends a multidisciplinary and interdisciplinary approach to all diabetes patients, regardless of age. The depression31 CPG provides a list of medications with low potential for drug-drug interactions. On the other hand, the osteoarthritis23 CPG leaves it to a physician’s discretion for how to handle comorbidities. The chronic obstructive pulmonary disease30 (COPD) CPG provides different treatment regimens for those with and those without comorbidities. Finally, the diabetes26 CPG recommends modification of glycemic targets among elderly patients with comorbidities. In addition, some CPGs provide recommendations on modification of treatment targets (diabetes26 CPG), comorbidites that warrant screening for lipid profiles (dyslipidemia25 CPG) or comorbidity-specific treatment recommendations (hypertension27 CPG).
Table 5.
CLINICAL PRACTICE GUIDELINE, BY DISEASE | COMORBIDITIES ADDRESSED | STATEMENTS AND RECOMMENDATIONS THAT ADDRESS PATIENTS WITH COMORBIDITIES (LEVELS OF EVIDENCE OR GRADES OF RECOMMENDATION*) |
---|---|---|
Congestive heart failure28 | Hypotension, myocardial infarction, hypertension, atrial fibrillation, diabetes, dementia, cognitive impairment, depression |
|
Chronic obstructive pulmonary disease30 | Ischemic heart disease, osteopenia, osteoporosis, glaucoma, cachexia, malnutrition, cancer, peripheral muscle dysfunction, ventricular arrhythmias |
|
Dementia32–38 | Diabetes, stroke, delirium, depression, peptic ulcers, heart block |
|
Depression31 | Postural hypotension, conduction disorders, hyponatremia, hypertension, congestive heart failure, bipolar disorder, dementia, bundle branch block, osteoporosis, myocardial infarction, HIV or AIDS, cancer, stroke, diabetes, Parkinson disease, seizure |
|
Diabetes26 | Dyslipidemia, hypertension, acute coronary syndromes, congestive heart failure, chronic kidney disease |
|
Dyslipidemia25 | Hypertension, obesity, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, chronic kidney disease, HIV |
|
Hypertension27 | Diabetes, renal disease, heart failure, peripheral vascular disease, transient ischemic attack, dyslipidemia, myocardial infarction |
|
Osteoarthritis23 | Gastrointestinal problems (eg, ulcers, bleeds, liver disease), cardiovascular diseases (eg, hypertension, ischemic heart disease, stroke, congestive heart failure), renal impairment, asthma, depression |
|
BP—blood pressure.
Levels of evidence and grades of recommendation are based on the categories used by individual articles.
Time to benefit in the context of life expectancy
Table 626,28,30,31 shows how several CPGs addressed issues related to treatment in the context of life expectancy. Four CPGs (CHF,28 COPD,30 diabetes,26 and depression31) discuss issues related to end-of-life care. The CHF,28 COPD,30 and diabetes26 CPGs recommend modification of treatment goals in accordance with prognosis and patient choice. The depression31 CPG recommends indefinite treatment of elderly patients with partial resolution of symptoms.
Table 6.
CLINICAL PRACTICE GUIDELINE, BY DISEASE | HOW TIME NEEDED TO TREAT ELDERLY PATIENTS TO BENEFIT IN THE CONTEXT OF LIFE EXPECTANCY WAS ADDRESSED (LEVELS OF EVIDENCE OR GRADES OF RECOMMENDATION*) |
---|---|
Congestive heart failure28 |
|
Chronic obstructive pulmonary disease30 |
|
Diabetes26 |
|
Depression31 |
|
Levels of evidence and grades of recommendation are based on the categories used by individual articles.
Barriers to implementation
Table 726–28,31–38 provides a summary of CPGs that list or discuss barriers to implementation. Most of the listed CPGs acknowledge gaps and a lack of good evidence for recommendations pertaining to the elderly population with or without comorbidities. Barriers to implementation are discussed in terms of adherence, polypharmacy, and difficulty in achieving treatment targets.
Table 7.
CLINICAL PRACTICE GUIDELINE, BY DISEASE | HOW BARRIERS TO IMPLEMENTATION WERE ADDRESSED |
---|---|
Diabetes26 |
|
Hypertension27 |
|
Congestive heart failure28 |
|
Depression31 |
|
Dementia32–38 |
|
Levels of evidence are based on the categories used by the individual article.
Evidence levels of recommendations
Recommendations in each guideline were generated by using different evidence grading systems. We list the available evidence level of the recommendations targeting elderly with comorbidities in Tables 323–28,30–38 to 7.26–28,31–38 The recommendations varied from grade A to grade D.
DISCUSSION
Elderly with or without comorbidities
We reviewed CPGs for 10 common chronic conditions managed by primary care physicians in elderly patients. This study has shown that most of these CPGs do mention the elderly population (7 out of the 10 CPGs, which is comparable to US13 and Australian14 studies). However, while most of the CPGs mention elderly patients, few of them adequately discuss issues related to elderly patients with comorbidities. Only 3 CPGs (CHF,28 diabetes,26 and depression31) have dedicated sections addressing elderly patients with comorbidities. The osteoarthritis23 and osteoporosis24 CPGs provide recommendations specific to elderly patients, but the recommendations are broad and nonspecific. The osteoarthritis23 and dementia32–38 CPGs have minimal discussions on issues pertaining to elderly patients with comorbidities. The dementia32–38 CPGs recommend that physicians stop medication if there is high risk of drug-to-drug interaction, although they did not specify common comorbidities that providers should be aware of.
Time needed to treat in the context of life expectancy
Only the CPGs for CHF,28 diabetes,26 and COPD30 specifically recommend modification of treatment in the context of life expectancy and patients’ preferences and prognoses. The other CPGs do not address issues related to time needed to treat to benefit in the context of life expectancy. This finding might be partly explained by the fact that primary studies often focus on evaluation of benefits rather than harms, which requires much more expensive longitudinal studies.39 Recently, one study focused on developing a payoff time framework, which might identify patients for whom particular clinical guidelines are unlikely to confer benefit; however, this framework has not been validated in a clinical setting.40
Barriers to implementation
Only half of the reviewed CPGs provide explicit statements on when or under what circumstances CPGs might be difficult to implement. Such statements address issues like treatment targets in the elderly, warnings about polypharmacy or drug-drug interactions, and the lack of evidence for some recommendations. Acknowledgment of barriers to implementation is an important component of continuous quality improvement of CPGs. By identifying and explicitly stating areas where it might be difficult to implement CPGs, strategies can then be developed to address the shortcomings and therefore improve the quality of CPGs or develop strategies to overcome the barriers.
Evidence level of recommendations
We found that very few recommendations for elderly with comorbidities were based on clinical trials (ie, grade A recommendations). This is not surprising, as most randomized trials exclude the elderly, especially those of advanced age or with comorbidities.39 It is estimated that only 5% of trials are designed specifically for elderly patients 65 years of age and older, and 15% of trials exclude elderly participants without any justification.41
Limitations
This is the first Canadian study that has attempted to study applicability of CPGs to elderly patients with comorbidities. Our study has several limitations. This study evaluated only 10 CPGs. The conditions discussed are the most common chronic conditions seen in the elderly and are managed largely by primary care physicians. Other diseases such as cancer and thyroid problems were not included but would likely be in the realm of both specialist and primary care providers. Second, there is no validated instrument to evaluate applicability of CPGs to elderly patients with comorbidities. We constructed our data collection sheet from different sources. We covered only 4 items that we believed were specific to the elderly and those with comorbidities. It is likely that there are other important domains that were not evaluated in this study. Future studies should develop and validate an instrument for assessing applicability of CPGs to elderly patients with comorbidities.
Conclusion
This study shows that only a handful of CPGs adequately address important issues common in the care of elderly patients. Given the demographic transition occurring in Canada, this is of urgent importance. Clearly, there is considerable room for improvement in these CPGs. There is a pressing need to improve the evidence base that undergirds the care of people of advanced age and with multiple concurrent chronic diseases.42 Guideline developers should include much more detailed information on management of elderly patients, with a particular emphasis on eliciting patient and caregiver concerns, setting clinical priorities, managing expectations (particularly around prognosis), and fostering optimum communication. This will aid in making CPGs more patient centred rather than disease driven. Based on this research, we propose that an ideal guideline should consider an open discussion about patients’ preferences, benefits of intervention in advanced age, time to benefit from treatment, trade-offs for function over disease control, as well as acknowledgment of uncertainty.
Acknowledgments
Dr Upshur is supported by the Canada Research Chair in Primary Care Research.
EDITOR’S KEY POINTS
Family physicians, who are the primary users of clinical practice guidelines (CPGs), are increasingly providing care to elderly patients with multiple comorbidities.
This article examines the applicability of common CPGs to elderly patients with comorbidities.
This study shows that only a handful of CPGs adequately address important issues common in the care of the elderly. Guideline developers should include much more detailed information on management of elderly patients, with a particular emphasis on eliciting patient and caregiver concerns, setting clinical priorities, managing expectations (particularly around prognosis), and fostering optimum communication. This will aid in making CPGs more patient centred rather than disease driven.
POINTS DE REPÈRE DU RÉDACTEUR
Les médecins de famille, qui sont les principaux utilisateurs des directives de pratique clinique (DPC), soignent de plus en plus de patients âgés présentant plusieurs affections.
Cet article cherche à savoir si les DPC générales s’appliquent aux patients âgés qui présentent des affections multiples.
Cette étude montre que très peu de DPC correspondent adéquatement aux importants problèmes fréquemment rencontrés chez les personnes âgées. Les concepteurs des directives devraient inclure des informations beaucoup plus détaillées sur le traitement des personnes âgées, en insistant particulièrement sur la nécessité de s’enquérir des préoccupations des patients et des intervenants, d’établir les priorités cliniques, de gérer les attentes (notamment au sujet du pronostic) et d’améliorer les communications. De cette façon, les DPC devraient être davantage centrées sur les patients plutôt que sur les maladies.
Footnotes
This article has been peer reviewed.
Cet article a fait l’objet d’une révision par des pairs.
Contributors
All authors contributed to the concept, analysis, drafting, and critical review of the article, and all approved the final version for submission.
Competing interests
None declared
References
- 1.Guideline summary. Rockville, MD: Agency for Healthcare Research and Quality; 2010. National Guideline Clearinghouse [websitel. Available from: www.guideline.gov/content.aspx?id=9538. Accessed 2011 May 25. [Google Scholar]
- 2.Ladouceur R. Guidelines are just ... guidelines! Can Fam Physician. 2007;53:595, 595. (Eng), (Fr). [Google Scholar]
- 3.Ladouceur R. Outside the guidelines, no salvation! Really? Can Fam Physician. 2010;56:510, 511. (Eng), (Fr). [PMC free article] [PubMed] [Google Scholar]
- 4.Gass D. Can family physicians practise good medicine without following clinical practice guidelines? No [Debate] Can Fam Physician. 2010;56:519, 521, 523, 525. (Eng); (Fr). [PMC free article] [PubMed] [Google Scholar]
- 5.Gass D. Can family physicians practise good medicine without following clinical practice guidelines? No [Rebuttal] Can Fam Physician. 2010;56:e207, e207. (Eng), (Fr). Available from: www.cfp.ca/content/56/6/e206.full.pdf+html. Accessed 2011 May 25. [PMC free article] [PubMed] [Google Scholar]
- 6.Upshur REG. Can family physicians practise good medicine without following clinical practice guidelines? Yes [Rebuttal] Can Fam Physician. 2010;56:e206, e208. (Eng), (Fr). Available from: www.cfp.ca/content/56/6/e206.full.pdf+html. Accessed 2011 May 25. [PMC free article] [PubMed] [Google Scholar]
- 7.Sehmer J. Adherence to osteoporosis guidelines [Letters] Can Fam Physician. 2008;54:1524. [PMC free article] [PubMed] [Google Scholar]
- 8.Upshur REG. Can family physicians practise good medicine without following clinical practice guidelines? Yes [Debate] Can Fam Physician. 2010;56:518, 520, 522, 524. (Eng); (Fr). [PMC free article] [PubMed] [Google Scholar]
- 9.McCormack JP, Loewen P. Adding “value” to clinical practice guidelines. Can Fam Physician. 2007;53:1326–7e.1–8. Available from: www.cfp.ca/content/53/8/1326.full.pdf+html. Accessed 2011 May 25. [PMC free article] [PubMed] [Google Scholar]
- 10.Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(20):1900–5. doi: 10.1001/jama.281.20.1900. [DOI] [PubMed] [Google Scholar]
- 11.Tinetti ME, Bogardus ST, Jr, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351(27):2870–4. doi: 10.1056/NEJMsb042458. [DOI] [PubMed] [Google Scholar]
- 12.Upshur RE, Tracy S. Chronicity and complexity. Is what’s good for the diseases always good for the patients? Can Fam Physician. 2008;54:1655–8. (Eng), CFPlus (Fr). [PMC free article] [PubMed] [Google Scholar]
- 13.Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. doi: 10.1001/jama.294.6.716. [DOI] [PubMed] [Google Scholar]
- 14.Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189(7):360–5. doi: 10.5694/j.1326-5377.2008.tb02079.x. [DOI] [PubMed] [Google Scholar]
- 15.Statistics Canada [website] Population projections for Canada, provinces and territories 2009 to 2036. Ottawa, ON: Statistics Canada; 2010. Available from: www.statcan.gc.ca/pub/91-520-x/91-520-x2010001-eng.htm. Accessed 2011 May 25. [Google Scholar]
- 16.Gilmour H, Park J. Dependency, chronic conditions and pain in seniors. Health Rep. 2006;16(Suppl):21–31. [PubMed] [Google Scholar]
- 17.Turcotte M, Schellenberg G. A portrait of seniors in Canada. Ottawa, ON: Statistics Canada; 2006. Available from: www.statcan.gc.ca/pub/89-519-x/89-519-x2006001-eng.pdf. Accessed 2011 May 25. [Google Scholar]
- 18.Bajcar JM, Wang L, Moineddin R, Nie JX, Tracy CS, Upshur RE. From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997–2006. BMC Fam Pract. 2010;11:75. doi: 10.1186/1471-2296-11-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Canadian Medical Association [website] CMA Infobase: clinical practice guidelines (CPGs) Ottawa, ON: Canadian Medical Association; 2011. Available from: www.cma.ca/clinicalresources/practiceguidelines. Accessed 2011 May 25. [Google Scholar]
- 20.AGREE Collaboration Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003;12(1):18–23. doi: 10.1136/qhc.12.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.AGREE Collaboration . Appraisal of guidelines for research and evaluation (AGREE) instrument. London, Engl: St George’s Hospital Medical School; 2001. Available from: www.agreecollaboration.org/pdf/agreeinstrumentfinal.pdf. Accessed 2011 May 25. [Google Scholar]
- 22.Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139(6):493–8. doi: 10.7326/0003-4819-139-6-200309160-00013. [DOI] [PubMed] [Google Scholar]
- 23.Guidelines and Protocols Advisory Committee . Osteoarthritis in peripheral joints—diagnosis and treatment. Vancouver, BC: British Columbia Ministry of Health Services; 2008. Available from: www.bcguidelines.ca/gpac/pdf/oa.pdf. Accessed 2011 May 25. [Google Scholar]
- 24.Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, et al. Canadian Consensus Conference on Osteoporosis. J Obstet Gynaecol Can. 2006;28(2 Suppl 1):S95–112. doi: 10.1016/s1701-2163(16)32087-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25(10):567–79. doi: 10.1016/s0828-282x(09)70715-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Canadian Diabetes Association Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(Suppl 1):S1–201. doi: 10.1016/j.jcjd.2013.01.009. [DOI] [PubMed] [Google Scholar]
- 27.Canadian Hypertension Education Program 2009 CHEP recommendations for the management of hypertension. Available from: http://hypertension.ca/chep/wp-content/uploads/2009/04/09-complete-recs.pdf. Accessed 2011 May 25.
- 28.Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22(1):23–45. doi: 10.1016/s0828-282x(06)70237-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Armstrong D, Marshall JK, Chiba N, Enns R, Fallone CA, Fass R, et al. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults—update 2004. Can J Gastroenterol. 2005;19(1):15–35. doi: 10.1155/2005/836030. [DOI] [PubMed] [Google Scholar]
- 30.O’Donnell DE, Hernandez P, Kaplan A, Aaron S, Bourbeau J, Marciniuk D, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J. 2008;15(Suppl A):1A–8A. doi: 10.1155/2008/641965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Buchanan D, Tourigny-Rivard M, Cappeliez P, Frank C, Janikowski P, Spanjevic L, et al. National guidelines for seniors’ mental health: the assessment and treatment of depression. Can J Geriatr. 2006;9(Suppl 2):S52–8. [Google Scholar]
- 32.Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ. 2008;179(10):1019–26. doi: 10.1503/cmaj.081103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179(8):787–93. doi: 10.1503/cmaj.070803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ. 2008;178(5):548–56. doi: 10.1503/cmaj.070796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, et al. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ. 2008;178(7):825–36. doi: 10.1503/cmaj.070798. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ. 2008;179(12):1279–87. doi: 10.1503/cmaj.070804. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Chertkow H, Massoud F, Nasreddine Z, Belleville S, Joanette Y, Bocti C, et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ. 2008;178(10):1273–85. doi: 10.1503/cmaj.070797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Chertkow H. Diagnosis and treatment of dementia: introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. CMAJ. 2008;178(3):316–21. doi: 10.1503/cmaj.070795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med. 2010;170(7):587–95. doi: 10.1001/archinternmed.2010.18. [DOI] [PubMed] [Google Scholar]
- 40.Braithwaite RS, Fiellin D, Justice AC. The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care. 2009;47(6):610–7. doi: 10.1097/MLR.0b013e31819748d5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.McMurdo ME, Witham MD, Gillespie ND. Including older people in clinical research. BMJ. 2005;331(7524):1036–7. doi: 10.1136/bmj.331.7524.1036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med. 2010;170(7):587–95. doi: 10.1001/archinternmed.2010.18. [DOI] [PubMed] [Google Scholar]